PE20110710A1 - Acidos naftilaceticos - Google Patents
Acidos naftilaceticosInfo
- Publication number
- PE20110710A1 PE20110710A1 PE2011001010A PE2011001010A PE20110710A1 PE 20110710 A1 PE20110710 A1 PE 20110710A1 PE 2011001010 A PE2011001010 A PE 2011001010A PE 2011001010 A PE2011001010 A PE 2011001010A PE 20110710 A1 PE20110710 A1 PE 20110710A1
- Authority
- PE
- Peru
- Prior art keywords
- naphthalen
- halogen
- acetic acid
- benzoyl
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/57—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and carboxyl groups, other than cyano groups, bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
- C07C317/46—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
- C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
- C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
- C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/70—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with ring systems containing two or more relevant rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
SE REFIERE A COMPUESTOS DERIVADOS DEL ACIDO NAFTALEN-2-IL-ACETICO DE FORMULA (I) DONDE Q ES C(H) O N; X ES C(O), C(H)(H), C(F)(F), ENTRE OTROS; R1 Y R2 SON CADA UNO H, HALOGENO, ALCOXI INFERIOR, ENTRE OTROS; R3 ES H, HALOGENO, CN, ALQUILO INFERIOR OPCIONALMENTE SUSTITUIDO CON HALOGENO, ENTRE OTROS; R4 ES HALOGENO, CICLOALQUILO INFERIOR, BENCILOXI, CN, ENTRE OTROS; R5 Y R6 SON CADA UNO H O METILO. SON COMPUESTOS PREFERIDOS: ACIDO [4-(4-DIMETILSULFAMOIL-BENZOIL)-NAFTALEN-2-IL]-ACETICO; ACIDO [6-FLUOR-4-(4-SULFAMOIL-BENZOIL)-NAFTALEN-2-IL]-ACETICO; ACIDO {4-[4-(3-CLORO-BENCENOSULFONIL)-BENZOIL]-6-FLUOR-NAFTALEN-2-IL}-ACETICO; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON ANTAGONISTAS O AGONISTAS PARCIALES DEL RECEPTOR "HELPER T" DE TIPO 2 (CRTH2) SIENDO UTILES EN EL TRATAMIENTO DE ASMA, ENFERMEDAD PULMONAR OBSTRUCTIVA CRONICA, RINITIS ALERGICA, INFLAMACION ALERGICA, DERMATITIS ATOPICA
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11514708P | 2008-11-17 | 2008-11-17 | |
US22223509P | 2009-07-01 | 2009-07-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20110710A1 true PE20110710A1 (es) | 2011-10-13 |
Family
ID=42062421
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2011001010A PE20110710A1 (es) | 2008-11-17 | 2009-11-09 | Acidos naftilaceticos |
Country Status (16)
Country | Link |
---|---|
US (1) | US8124629B2 (es) |
EP (1) | EP2346807A1 (es) |
JP (1) | JP2012508715A (es) |
KR (1) | KR20110071122A (es) |
CN (1) | CN102216249A (es) |
AR (1) | AR074353A1 (es) |
AU (1) | AU2009315713A1 (es) |
BR (1) | BRPI0921254A2 (es) |
CA (1) | CA2740864A1 (es) |
IL (1) | IL212120A0 (es) |
MX (1) | MX2011005200A (es) |
PE (1) | PE20110710A1 (es) |
RU (1) | RU2011124149A (es) |
TW (1) | TWI385145B (es) |
WO (1) | WO2010055005A1 (es) |
ZA (1) | ZA201102525B (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102099341B (zh) | 2008-07-15 | 2013-07-10 | 霍夫曼-拉罗奇有限公司 | 氨基四氢吲唑基乙酸类 |
EP2346819B1 (en) * | 2008-11-17 | 2013-04-10 | F. Hoffmann-La Roche AG | Naphthylacetic acids |
JP5373104B2 (ja) * | 2008-11-17 | 2013-12-18 | エフ.ホフマン−ラ ロシュ アーゲー | Crth2アンタゴニスト又は部分アゴニストとして使用されるナフチル酢酸 |
EP2457900A1 (en) | 2010-11-25 | 2012-05-30 | Almirall, S.A. | New pyrazole derivatives having CRTh2 antagonistic behaviour |
US8470884B2 (en) | 2011-11-09 | 2013-06-25 | Hoffmann-La Roche Inc. | Alkenyl naphthylacetic acids |
US9000044B2 (en) | 2012-02-28 | 2015-04-07 | Hoffmann-La Roche Inc. | Substituted naphthylacetic acids |
UY36548A (es) | 2015-02-05 | 2016-06-01 | Bayer Cropscience Ag | Derivados heterocíclicos condensados bicíclicos sustituidos por 2-(het)arilo como pesticidas |
CN114609263B (zh) * | 2021-11-30 | 2024-06-18 | 苏州正济药业有限公司 | 一种(r)-2,4-二碘-3-甲基-1-烯及其对映异构体的检测方法 |
CN114573557B (zh) * | 2022-03-28 | 2024-03-08 | 浙江天宇药业股份有限公司 | 一种奥特康唑的制备方法 |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3899529A (en) | 1973-02-22 | 1975-08-12 | Merck & Co Inc | Aroyl substituted naphthalene acetic acids |
US4443462A (en) | 1979-08-06 | 1984-04-17 | Merrell Dow Pharmaceuticals Inc. | Antipsychotic 4-(naphthalenyloxy)piperidine derivatives |
US4371537A (en) | 1981-08-13 | 1983-02-01 | The Dow Chemical Company | Sulfur-substituted phenoxypyridines having antiviral activity |
DE3631824A1 (de) | 1986-02-21 | 1988-03-31 | Bayer Ag | Cycloalkano(1.2-b)indol-sulfonamide |
DE3623941A1 (de) | 1986-07-16 | 1988-01-28 | Bayer Ag | Substituierte amino-5,6,7,8-tetrahydronaphthyl-oxyessigsaeuren, verfahren zu deren herstellung sowie die verwendung als arzneimittel |
EP0405602A1 (en) | 1989-06-30 | 1991-01-02 | Laboratorios Vinas S.A. | New Zinc derivatives of anti-inflammatory drugs having improved therapeutic activity |
FR2665159B1 (fr) | 1990-07-24 | 1992-11-13 | Rhone Poulenc Sante | Nouveaux derives de la pyridine et de la quinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent. |
DE4235155A1 (de) | 1992-10-19 | 1994-04-21 | Basf Ag | Verfahren zur Herstellung von Methylsulfonylbenzoesäuren |
JP2562405B2 (ja) | 1993-04-06 | 1996-12-11 | 花王株式会社 | ケラチン繊維処理剤組成物 |
DE69410956T2 (de) | 1993-12-09 | 1999-03-25 | Ono Pharmaceutical Co | Naphthylessigsäurederivate als PGEZ Agonisten und Antagonisten |
AUPP609198A0 (en) | 1998-09-22 | 1998-10-15 | Curtin University Of Technology | Use of non-peptidyl compounds for the treatment of insulin related ailments |
PL369129A1 (en) | 2001-09-28 | 2005-04-18 | Intermune, Inc. | Method for treating hepatitis c virus infection in treatment failure patients |
AU2003231509A1 (en) | 2002-05-16 | 2003-12-02 | Shionogi And Co., Ltd. | Compound exhibiting pgd 2 receptor antagonism |
ATE327977T1 (de) * | 2002-10-21 | 2006-06-15 | Warner Lambert Co | Tetrahydrochinolin-derivate als crth2 antagonisten |
EP1413306A1 (en) * | 2002-10-21 | 2004-04-28 | Warner-Lambert Company LLC | Tetrahydroquinoline derivatives as CRTH2 antagonists |
US20070161698A1 (en) * | 2003-05-30 | 2007-07-12 | Microbia, Inc. | Modulators of CRTH2 Activity |
CA2527114A1 (en) * | 2003-05-30 | 2004-12-16 | Microbia, Inc. | Methods for the protection of memory and cognition |
CN1849121A (zh) | 2003-06-20 | 2006-10-18 | 安姆根有限公司 | 作为缓激肽拮抗剂的哌嗪衍生物 |
JP2007508363A (ja) | 2003-10-14 | 2007-04-05 | オキサジェン リミテッド | Crth2アンタゴニスト活性を有する化合物 |
SE0303180D0 (sv) | 2003-11-26 | 2003-11-26 | Astrazeneca Ab | Novel compounds |
US7226951B2 (en) | 2003-12-17 | 2007-06-05 | Allergan, Inc. | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same |
MX2007003335A (es) | 2004-09-21 | 2007-06-05 | Athersys Inc | Acidos aceticos de bencimidazol que muestran antagonismo de receptor crth2 y usos de los mismos. |
CA2580461A1 (en) | 2004-09-23 | 2006-04-06 | Amgen Inc. | Substituted sulfonamidopropionamides and methods of use |
KR100889185B1 (ko) | 2004-12-21 | 2009-03-16 | 에프. 호프만-라 로슈 아게 | 테트랄린 및 인단 유도체 및 5-ht 길항제로서의 이의용도 |
UA90706C2 (ru) | 2005-02-24 | 2010-05-25 | Милленниум Фармасьютикалз, Инк. | Антагонисты рецептора pgd2 для лечения воспалительных заболеваний |
CA2619450C (en) | 2005-09-01 | 2013-10-22 | Eli Lilly And Company | 6-n-linked heterocycle-substituted 2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists |
GB0518783D0 (en) * | 2005-09-14 | 2005-10-26 | Argenta Discovery Ltd | Indolizine compounds |
CN101273013B (zh) * | 2005-09-27 | 2013-06-12 | 盐野义制药株式会社 | 具有pgd2受体拮抗活性的磺酰胺衍生物 |
AU2006296004B2 (en) | 2005-09-27 | 2011-11-17 | Shionogi & Co., Ltd. | Sulfonamide derivative having PGD2 receptor antagonistic activity |
JP2009541219A (ja) * | 2006-06-12 | 2009-11-26 | メルク エンド カムパニー インコーポレーテッド | 高眼圧治療のための眼科組成物 |
MX2009006762A (es) * | 2006-12-21 | 2009-08-20 | Argenta Discovery Ltd | Antagonistas crth2. |
CN102099341B (zh) | 2008-07-15 | 2013-07-10 | 霍夫曼-拉罗奇有限公司 | 氨基四氢吲唑基乙酸类 |
ES2378755T3 (es) | 2008-07-15 | 2012-04-17 | F. Hoffmann-La Roche Ag | �?cidos aminotetrahidroindazoloacéticos |
EP2321267A2 (en) | 2008-08-15 | 2011-05-18 | F. Hoffmann-La Roche AG | Monoaryl aminotetralines |
CA2734104A1 (en) | 2008-08-15 | 2010-02-18 | F. Hoffmann-La Roche Ag | Substituted aminotetralines |
CA2735392A1 (en) | 2008-08-15 | 2010-02-18 | F. Hoffmann-La Roche Ag | Bi-aryl aminotetralines |
EP2346819B1 (en) | 2008-11-17 | 2013-04-10 | F. Hoffmann-La Roche AG | Naphthylacetic acids |
JP5373104B2 (ja) | 2008-11-17 | 2013-12-18 | エフ.ホフマン−ラ ロシュ アーゲー | Crth2アンタゴニスト又は部分アゴニストとして使用されるナフチル酢酸 |
-
2009
- 2009-11-09 EP EP09748339A patent/EP2346807A1/en not_active Withdrawn
- 2009-11-09 AU AU2009315713A patent/AU2009315713A1/en not_active Abandoned
- 2009-11-09 BR BRPI0921254A patent/BRPI0921254A2/pt not_active IP Right Cessation
- 2009-11-09 RU RU2011124149/04A patent/RU2011124149A/ru not_active Application Discontinuation
- 2009-11-09 MX MX2011005200A patent/MX2011005200A/es active IP Right Grant
- 2009-11-09 CN CN2009801459479A patent/CN102216249A/zh active Pending
- 2009-11-09 KR KR1020117011096A patent/KR20110071122A/ko active IP Right Grant
- 2009-11-09 US US12/614,478 patent/US8124629B2/en not_active Expired - Fee Related
- 2009-11-09 WO PCT/EP2009/064813 patent/WO2010055005A1/en active Application Filing
- 2009-11-09 JP JP2011535982A patent/JP2012508715A/ja not_active Ceased
- 2009-11-09 CA CA2740864A patent/CA2740864A1/en not_active Abandoned
- 2009-11-09 PE PE2011001010A patent/PE20110710A1/es not_active Application Discontinuation
- 2009-11-16 TW TW098138886A patent/TWI385145B/zh not_active IP Right Cessation
- 2009-11-16 AR ARP090104426A patent/AR074353A1/es not_active Application Discontinuation
-
2011
- 2011-04-04 IL IL212120A patent/IL212120A0/en unknown
- 2011-04-05 ZA ZA2011/02525A patent/ZA201102525B/en unknown
Also Published As
Publication number | Publication date |
---|---|
RU2011124149A (ru) | 2012-12-27 |
ZA201102525B (en) | 2012-09-26 |
EP2346807A1 (en) | 2011-07-27 |
MX2011005200A (es) | 2011-06-01 |
KR20110071122A (ko) | 2011-06-28 |
AU2009315713A1 (en) | 2010-05-20 |
JP2012508715A (ja) | 2012-04-12 |
US20100137250A1 (en) | 2010-06-03 |
BRPI0921254A2 (pt) | 2018-10-23 |
CN102216249A (zh) | 2011-10-12 |
WO2010055005A1 (en) | 2010-05-20 |
IL212120A0 (en) | 2011-06-30 |
TW201022197A (en) | 2010-06-16 |
TWI385145B (zh) | 2013-02-11 |
AR074353A1 (es) | 2011-01-12 |
CA2740864A1 (en) | 2010-05-20 |
US8124629B2 (en) | 2012-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20110710A1 (es) | Acidos naftilaceticos | |
PE20110703A1 (es) | Acidos naftilaceticos | |
PE20090622A1 (es) | Nuevos derivados de bencimidazol sustituido | |
ATE538100T1 (de) | Aminotetrahydroindazoloessigsäuren | |
PE20080186A1 (es) | Derivados 4,6-disustituidos de 2-metoxi-6-etilamino-pirimidina como antagonistas del receptor de prostaglandina d2 | |
PE20091734A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
PE20070362A1 (es) | COMPUESTOS DERIVADOS DE INDAZOL-4-IL-2,4-PIRIMIDINDIAMINA COMO INHIBIDORES DE TIROSINA QUINASA (QUINASA Syk) | |
PE20110237A1 (es) | Derivados de ciclohexilamida como antagonistas del receptor del factor de liberacion de corticotropina (crf-1) | |
PE20090886A1 (es) | Nuevos inhibidores de quinasa | |
PE20120056A1 (es) | Derivados de indol como antagonistas del receptor crth2 | |
NO341591B1 (no) | 3-Z-[1-(4-(N-((4-metyl-piperazin-1-yl)-metylkarbonyl)-N-metyl-amino)-anilino)-1-fenyl-metylen]-6-metoksykarbonyl-2-indolinon, tautomerene, diastereomerene, enantiomerene, blandinger derav og saltene derav, og i kombinasjon med en ytterligere farmakologisk aktiv substans, for anvendelse i forebygging eller behandling av fibrose ved revmatoid artritt | |
PE20060949A1 (es) | Derivados fusionados de pirazol como agonistas del receptor de niacina | |
PE20141375A1 (es) | Activadores de glucoquinasa | |
PE20081505A1 (es) | Inhibidores de serina palmitoiltransferasa | |
PE20120135A1 (es) | Piperidinas sustituidas como antagonistas de ccr3 | |
PE20060736A1 (es) | DERIVADOS DE PIRROL COMO ANTAGONISTAS DE CRTh2 | |
PE20121050A1 (es) | Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog | |
PE20121640A1 (es) | Derivados de pirazina como inhibidores de bace | |
CY1115873T1 (el) | Νεοι ανταγωνιστες υποδοχεα ccr2 και χρησεις αυτων | |
EA201170705A1 (ru) | Арилметилбензохиназолиноны в качестве позитивных аллостерических модуляторов рецептора м1 | |
JP2008513504A5 (es) | ||
PE20110410A1 (es) | Derivado de 7-piperidinoalquil-3,4-dihidroquinolona | |
NZ614305A (en) | Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases | |
ATE402935T1 (de) | Kondensierte heterocyclische verbindungen und deren verwendung als antagonisten des metabotropen rezeptors zur behandlung von gastrointestinalen erkrankungen | |
PE20110928A1 (es) | Derivados de 4-azetidinil-1-heteroaril-ciclohexanol como antagonistas de ccr2 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |